Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
ID: 351912Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351912

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-095.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity aimed at supporting the analytical validation of candidate biomarkers for neurological and neuromuscular disorders through cooperative agreements (U01). This initiative requires applicants to demonstrate the unmet need for the biomarker(s) and specify their contexts of use, with a strong emphasis on establishing robust analytical validation that addresses accuracy, precision, sensitivity, and specificity across testing sites. The program encourages diverse research teams and mandates a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusive scientific innovation. Applications are due by June 22, 2026, with no explicit budget limit, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-095.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-095-Full-Announcement.html
    PAR-24-095.html
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), has issued a funding opportunity (NOFO) aimed at supporting the analytical validation of biomarkers for neurological and neuromuscular disorders. This initiative includes cooperative agreements (U01) for research projects and highlights the necessity for applications to demonstrate the unmet need for the biomarker(s) and specify contexts of use. A critical emphasis is on establishing robust analytical validation that addresses accuracy, precision, sensitivity, and specificity across testing sites. The requirement for a Plan for Enhancing Diverse Perspectives (PEDP) is highlighted, with a focus on fostering inclusive research teams to enhance scientific innovation. Applications must include detailed plans addressing project milestones, management, and collaborative efforts among diverse researchers and institutions. The funding is project period is capped at 4 years with no explicit budget limit, requiring a health and scientifically rigorous rationale for any funding requests. The document outlines comprehensive application procedures, including strict adherence to submission guidelines and the importance of early contact with NIH program staff. Applications not aligned with the scope, including those primarily focused on clinical trials or lacking required components, will be considered non-responsive and withdrawn from review.
    Similar Opportunities
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders," aimed at supporting the rigorous analytical validation of biomarker measurement methods for neurological diseases. This initiative seeks proposals from small businesses to conduct analytical validation, requiring applicants to justify their chosen biomarkers, outline contexts of use, and include a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research. Grants are available under U44 Small Business Innovation Research (SBIR) cooperative agreements, with funding amounts up to $700,000 annually for Phase I and up to $1.5 million for Phase II, and applications are due by June 25, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-098.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Analytical and Clinical Validation of Biomarkers for Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD)" (PAR-23-258), aimed at supporting the validation of biomarkers to enhance therapy development and clinical practices. This initiative seeks applications that focus on achieving rigorous analytical and clinical validation of biomarkers, aligning with the standards set by the FDA’s Biomarker Qualification Program. The program is crucial for advancing research strategies that validate candidate biomarkers across diverse populations, thereby facilitating their use in clinical trials and medical product development. Interested applicants, including various educational and community organizations, must submit their proposals by March 6, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (U01), aimed at supporting Investigational New Drug (IND)-enabling studies and clinical trial planning for innovative gene-based therapeutics targeting ultra-rare diseases affecting fewer than 6,000 individuals. The program seeks to advance promising therapeutic candidates through robust proof-of-concept data and facilitate the submission of IND applications to the FDA, thereby addressing significant unmet medical needs within the ultra-rare disease community. Eligible applicants include higher education institutions, nonprofits, and governmental agencies, with a project period not exceeding two years and application deadlines ranging from October 2023 to February 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided NIH link.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at validating biomarker assays developed through NIH-supported research grants, specifically under the R01 mechanism, with a focus on enhancing their clinical application for cancer detection and treatment. This initiative seeks to accelerate the translation of molecular, cellular, and imaging markers into clinical settings, encouraging multidisciplinary collaborations among scientists, clinicians, and laboratory experts to adapt and validate these biomarkers for various cancer-related purposes. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with funding available up to $150,000 for a project period of up to three years. Interested parties should note that the application deadline is October 13, 2026, and can find further details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Institute of Dental and Craniofacial Research (NIDCR) for investigator-initiated observational studies or biomarker validation studies that require prospective data collection. This cooperative agreement aims to support research that enhances oral health by generating robust clinical data and validating biomarkers with established preliminary data. The funding is available for projects up to five years, contingent upon NIH appropriations, and emphasizes the significance of the proposed research and the investigator's capability. Interested applicants can find more information and application guidelines at the provided link, with the application due date set for May 7, 2026, and inquiries directed to grantsinfo@nih.gov.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.